This week’s spotlight was dominated by the US’s decision to bring the controversial right-to-try policy into law and by the EU’s decision to allow Bayer to buy Monsanto. In other news, Thursday was World No Tobacco day and the US is reported to have over 1,000 potential drugs to treat oncology in its pipeline.
Doctors reported that the Mexican government spent MX$151 billion to treat obesity last year and an announcement was made that Puebla will have its first medical waste management plant. On Thursday, Guanajuato hosted CannaMex World Summit, which brought together experts to discuss the benefits of cannabis products in a wide range of fields, from medicine to technology. On a related topic, CEPAL suggested that Latin America would benefit from the legalization of drugs.
Mexico Health Review spoke to Aspen Labs’ Raul Camarena on the company’s strategies in Mexico, which are allowing the company to grow at double the market rate.
Now jump into last week’s highlights:
With an investment of MX$7 million, Puebla plans the construction of its first medical waste management plant.
Mexico spent almost MX$151 billion treating overweight and obesity during 2017, said doctors during the Obesity Expert Meeting held in Jalisco.
June 31 was World No Tobacco Day a global initiative to increase awareness of the numerous dangers of smoking.
The US approves controversial right-to-try policy, which gives terminally ill patients access to drugs not yet approved by the FDA. The chief sponsor of this new law said that its goal was to “diminish the FDA’s power over people’s lives.”
The Economic Commission of Latin America and the Caribbean (CEPAL) suggested that the region would benefit from the legalization of drugs, as their illegality is causing deaths.
The EU gave Bayer approval to buy Monsanto for US$66 billion, if the first divests US$9 billion of its agricultural business. The divestiture was intended as an antitrust measure. Bayer agreed to sell its US$9 billion worth of assets to BASF.
New report indicates that the US has over 1,000 oncology drugs in development, a sharp increase on previous years.